Docoh
Loading...

KMDA Kamada

Kamada Ltd. (the 'Company') is a global specialty plasma-derived biopharmaceutical company with a diverse portfolio of marketed products, a robust development pipeline and industry-leading manufacturing capabilities. The Company's strategy is focused on driving profitable growth from its current commercial products, its plasma-derived development pipeline and its manufacturing expertise, while evolving into a vertically integrated plasma-derived company. The Company's two leading commercial products are GLASSIA® and KEDRRAB®. GLASSIA was the first liquid, ready-to-use, intravenous plasma-derived AAT product approved by the FDA. The Company markets GLASSIA in the U.S. through a strategic partnership with Takeda Pharmaceuticals Company Limited ('Takeda') and in other countries through local distributors. Pursuant to an agreement with Takeda, the Company will continue to produce GLASSIA for Takeda through 2021 and Takeda will initiate its own production of GLASSIA for the U.S. market in 2021, at which point Takeda will commence payment of royalties to the Company until 2040. KEDRAB is an FDA approved anti-rabies immune globulin (Human) for post-exposure prophylaxis treatment. KEDRAB is being marketed in the U.S. through a strategic partnership with Kedrion S.p.A. The Company has additional four plasma-derived products administered by injection or infusion, that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, Argentina, India and other countries in Latin America and Asia. The Company has two leading development programs; a plasma-derived hyperimmune immunoglobulin (IgG) product as a potential treatment for coronavirus disease (COVID-19) and an inhaled AAT for the treatment of AAT deficiency for which the Company is currently conducting the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial. The Company leverages its expertise and presence in the Israeli pharmaceutical market to distribute in Israel more than 20 products that are manufactured by third parties and have recently added nine biosimilar products to its Israeli distribution portfolio, which, subject to EMA and the Israeli MOH approvals, are expected to be launched in Israel between the years 2022 and 2025. FIMI Opportunity Fund, the leading private equity investor in Israel, is the Company's lead shareholder, beneficially owning approximately 21% of the outstanding ordinary shares.

KMDA stock data

(
)

Calendar

24 Feb 21
20 Oct 21
31 Dec 21
Quarter (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Kamada earnings reports.

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

53.0% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 56 44 +27.3%
Opened positions 16 7 +128.6%
Closed positions 4 12 -66.7%
Increased positions 12 10 +20.0%
Reduced positions 12 15 -20.0%
13F shares
Current Prev Q Change
Total value 157.37M 161.67M -2.7%
Total shares 23.73M 23.02M +3.1%
Total puts 1.8M 20.6K +8642.2%
Total calls 0 0
Total put/call ratio Infinity Infinity NaN%
Largest owners
Shares Value Change
Davidi Ishay 9.45M $69.19M 0.0%
Gov Financial 2.9M $18.76M 0.0%
Hahn Jonathan 1.9M $12.34M 0.0%
Brosh Capital Partners 1.73M $11.86M 0.0%
Renaissance Technologies 1.12M $6.53M -7.6%
Acadian Asset Management 1.11M $6.52M +28.3%
PXGPE Phoenix 921.66K $5.36M 0.0%
ARK Investment Management 915.01K $5.36M +5.6%
Altshuler Shaham 905.25K $5.3M +232.8%
Vanguard 755.29K $4.4M +0.3%
Largest transactions
Shares Bought/sold Change
Altshuler Shaham 905.25K +633.21K +232.8%
BLK Blackrock 17.38K -374.78K -95.6%
Acadian Asset Management 1.11M +245.16K +28.3%
Renaissance Technologies 1.12M -91.8K -7.6%
JEF Jefferies 89.49K +89.49K NEW
Alps Advisors 0 -80.94K EXIT
NMR Nomura 74.75K +74.75K NEW
ARK Investment Management 915.01K +48.64K +5.6%
Seizert Capital Partners 93.83K +47.82K +103.9%
Legato Capital Management 47.68K +47.68K NEW

Financial report summary

?
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: ACC, ADMA, Adom, Air, Allergy, Amiad, amplify, apprised, Ari, arriving, assembling, Assuta, bamlanivimab, BATM, Beaumont, Ben, Berkeley, Biartrate, Biden, BioMed, broadening, Buy, casirivimab, cast, CMO, cocktail, Colonel, Commonwealth, cum, curb, Cysteamine, deadline, Dean, dedicated, depletion, dissolve, distancing, divested, donate, DSMB, dual, Elyakim, era, erosion, expedited, finite, floating, footnote, fore, freight, fringe, Gan, GC, guiding, Gurion, holistic, hyperimmune, Ig, imdevimab, inbound, incorrectly, incurrence, infrastructure, InnovAAT, Inpatient, intramuscular, Island, ITAC, Joe, judge, Kanabo, laude, Liminal, LSE, MADA, Magen, Magna, marking, mild, misaligned, mobilizing, multiplied, nephropathic, NIAID, NIH, Norway, obligor, obliterate, Octapharma, outbound, Oxford, oxidation, pandemic, parallel, perspective, Philip, pig, Plastic, played, Ploeg, polyclonal, precipitate, prejudice, Procysbi, qualitative, quantitative, rabid, ramp, ramping, referenced, Regeneron, reluctance, reportedly, restraining, RFR, Rhode, Rimoni, robust, safeguard, Sanquin, Saol, Secretary, sector, Sheba, shortfall, snap, sooner, sovereignty, speed, stay, steeper, step, stronger, Surgeon, Tadir, TCJA, Therapix, therewith, transitionary, tribunal, TX, unconditional, unprecedented, uptake, variance, vertically, wake, western, widespread, workforce, worth, Yifat
Removed: absent, abstain, abstention, acquirer, adversarial, AEs, affirmative, alive, allogeneic, appraisal, attacked, attenuate, automatic, Behar, Beilinson, Belinson, BMT, bond, bone, BOS, calling, cancer, chiesi, complication, convenient, convinced, convincingly, cultural, database, delivering, diagnose, diagnostical, die, Diffusing, DLCO, Dohme, dyspnea, enabling, encouraging, episode, expressing, farmaceutici, favorably, Ferrara, filer, gastrointestinal, generation, half, Hematology, hematopoietic, HIV, HSCT, Icahn, Idiopathic, Immunology, immunosuppressant, inexpensive, inhaling, intervention, invent, ITT, John, Kramer, leader, lessen, Levine, lieu, lived, MAGIC, marrow, medium, Merck, merged, merging, Mizrahi, Mordechai, mucosal, nominal, objected, Obstructive, offeree, offeror, Oncological, output, Panama, peak, pharmacovigilance, possession, prediction, prednisone, preference, prepare, preserved, proportion, Rabin, reallocating, recognizing, reconvened, reject, renewable, renowned, repatriable, Reuven, Room, ROW, Sackler, saving, Schneider, score, send, Sharp, signal, simply, skin, SOC, specialist, stabilized, Stein, stem, Street, subtracted, subtracting, suggested, summarize, survival, survived, symptom, Syndrome, systemic, takeover, Tefahot, Tisch, top, topline, transferrin, transplanted, trick, undergoing, understood, Unsecured, ventia, voluntary, Washington

Proxies

No filings